CNTX Stock Analysis: Buy, Sell, or Hold?
CNTX - Context Therapeutics Inc. Common Stock
$0.63
0.03 (5.32%)
▲
5d:
-55.5%
30d:
-70.88%
90d:
-78.87%
WAIT
LOW Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Get Alerted When CNTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: CNTX is down 55.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: CNTX is down 55.5% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: CNTX is currently trading at $0.63, which is considered oversold relative to its 30-day fair value range of $1.29 to $2.69.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.58, while resistance sits at $2.23. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.43 (+759.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, CNTX is in a downtrend. Immediate support is located at $0.58, while resistance sits at $2.23. The stock is showing strong short-term momentum, up 5.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $5.43 (+759.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.29 -
$2.69
Company Quality Score
41/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: Strong upward momentum (+5.3%)
- BULLISH: Trading 759.1% below Wall St target ($5.43)
- WARNING: Recommendation downgraded due to -55.5% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$1.29 -
$2.69
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.58
Resistance Level
$2.23
Current Trend
Downtrend
Technical data as of
Jun 17, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.46
Wall Street Target
$5.43
(+759.1%)
Share & Embed Analysis
Last updated: June 21, 2026 3:13 PM ET
Data refreshes hourly during market hours. Next update: 4:13 PM
Data refreshes hourly during market hours. Next update: 4:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CNTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 60 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
